Based in Woburn, Massachusetts, Intrinsic Therapeutics is a medical device company that has developed an innovative spine implant solution for patients who undergo lumbar discectomy. An emphasis with Intrinsic Therapeutic’s Barricaid® device is on preventing reherniations after discectomy surgery.

Fulfilling clinical promise, the Intrinsic Therapeutics device works in closing large defects within the annulus, which often result in reherniation and reoperation. The permanent implant has two major elements, an anchor and an occlusion component, with the latter crafted from a flexible polymer material. The anchor is crafted of titanium alloy and employed in securing the Barricaid in position.

The safety and reliability of Intrinsic Therapeutics’ device has been extensively tested over two years of FDA research and screening. Study results of the FDA approved technology have made available in The Spine Journal (May 2018). In addition, the health-economic benefits of the bone-anchored annular closure device versus traditional lumbar discectomy approaches have been published in The Spine Journal.